MX2018009225A - Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. - Google Patents

Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.

Info

Publication number
MX2018009225A
MX2018009225A MX2018009225A MX2018009225A MX2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A
Authority
MX
Mexico
Prior art keywords
vectors
subject
frameshift
mutation
disease
Prior art date
Application number
MX2018009225A
Other languages
English (en)
Inventor
Petit Robert
F Princiotta Michael
PERRY Kyle
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MX2018009225A publication Critical patent/MX2018009225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición de inmunoterapia personalizada para un sujeto que padece una enfermedad o trastorno, que incluye vectores de administración de vacuna terapéutica y a métodos para preparar la misma, que comprenden construcciones de expresión génica que expresan péptidos derivados de mutaciones de modificación del marco asociados con uno o más neoepítopos codificados por secuencias de ácido nucleico que comprenden por lo menos una mutación de modificación del marco, en donde la mutación de modificación del marco es específica del cáncer o tejido no sano del sujeto. El vector de distribución o administración de la presente invención incluye vectores bacterianos, o vectores virales, o vectores de vacuna peptídica; o vectores de vacuna de ADN que incluyen vectores bacterianos de Listeria que comprenden una o más proteínas de fusión, que comprenden uno o más péptidos derivados de mutaciones de modificación del marco, que contienen uno o más neoepítopos presentes en muestras biológicas portadoras de la enfermedad provenientes del sujeto. También se describen métodos para el uso de estas composiciones para inducir una respuesta inmunitaria contra la enfermedad o trastorno, incluyendo un tumor o cáncer, o una infección, en el sujeto.
MX2018009225A 2016-01-27 2017-01-27 Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. MX2018009225A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662287871P 2016-01-27 2016-01-27
PCT/US2017/015403 WO2017132547A1 (en) 2016-01-27 2017-01-27 Personalized delivery vector-based immunotherapy and uses thereof

Publications (1)

Publication Number Publication Date
MX2018009225A true MX2018009225A (es) 2019-08-21

Family

ID=59398812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009225A MX2018009225A (es) 2016-01-27 2017-01-27 Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.

Country Status (11)

Country Link
US (1) US20190032064A1 (es)
EP (1) EP3408395A4 (es)
JP (1) JP2019503186A (es)
KR (1) KR20180100443A (es)
CN (1) CN108884468A (es)
AU (1) AU2017211387A1 (es)
CA (1) CA3012829A1 (es)
MA (1) MA47398A (es)
MX (1) MX2018009225A (es)
SG (1) SG11201806392XA (es)
WO (1) WO2017132547A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis ADJUVANZIA ON LISTERIA BASE
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
WO2015126921A1 (en) 2014-02-18 2015-08-27 Advaxis, Inc. Biomarker directed multi-target immunotherapy
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) * 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
SG10202105561PA (en) 2016-11-30 2021-07-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
MX2020003100A (es) 2017-09-19 2020-08-20 Advaxis Inc Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria.
SG11202008539YA (en) * 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
CN111334521B (zh) * 2018-12-18 2022-02-18 上海若泰医药科技有限公司 一种提高非整合减毒李斯特菌外源抗原蛋白表达的方法
CA3131824A1 (en) * 2019-03-11 2020-09-17 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
CA3161242A1 (en) * 2019-12-18 2021-06-24 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
CA3178487A1 (en) * 2020-05-14 2021-11-18 Daniel Omar FRIMANNSSON Polynucleotides comprising an antigenic payload

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2009143085A1 (en) * 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comprising prfa*mutant listeria and methods of use thereof
WO2015126921A1 (en) * 2014-02-18 2015-08-27 Advaxis, Inc. Biomarker directed multi-target immunotherapy

Also Published As

Publication number Publication date
US20190032064A1 (en) 2019-01-31
CA3012829A1 (en) 2017-08-03
KR20180100443A (ko) 2018-09-10
CN108884468A (zh) 2018-11-23
SG11201806392XA (en) 2018-08-30
JP2019503186A (ja) 2019-02-07
AU2017211387A1 (en) 2018-08-16
EP3408395A1 (en) 2018-12-05
EP3408395A4 (en) 2019-12-11
MA47398A (fr) 2019-12-11
WO2017132547A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
MX2017015149A (es) Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
EP3424524A3 (en) Cancer rna-vaccine
CR20190594A (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
EP4032544A3 (en) Novel t cell receptors and immune therapy using the same
CA3045233A1 (en) Novel t cell receptors and immune therapy using the same
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
WO2017077329A3 (en) Nucleic acids, peptides and methods
PH12019500312A1 (en) T cell receptors and immune therapy using the same
CN107072184A (zh) 嵌合抗原受体
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
JP2018528237A5 (es)
WO2008084115A3 (en) Lactococcus promoters and uses thereof
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
JP2014510519A5 (es)
MX2018010850A (es) Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
ES2605020T3 (es) Composición de ADN para inducir una respuesta inmunitaria contra macrófagos asociados a tumor
NZ760008A (en) Uti fusion proteins
PH12015501467A1 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
CN103360497A (zh) 一种新型抗肿瘤融合蛋白疫苗及其制备方法和应用